Provided by Tiger Fintech (Singapore) Pte. Ltd.

BioLine Rx

2.65
-0.2900-9.86%
Post-market: 2.790.1399+5.28%18:07 EDT
Volume:55.82K
Turnover:152.96K
Market Cap:9.86M
PE:-0.57
High:2.90
Open:2.84
Low:2.58
Close:2.94
Loading ...

Company Profile

Company Name:
BioLine Rx
Exchange:
NASDAQ
Establishment Date:
2003
Employees:
79
Office Location:
Modi’in Technology Park,2 HaMa’ayan Street,Hevel Modi'in,Israel
Zip Code:
7177871
Fax:
972 8 642 9101
Introduction:
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Directors

Name
Position
Aharon Schwartz
Chairman of the Board
Avraham Molcho
External Director
Nurit Benjamini
External Director
B.J. Bormann
Director
Michael J. Anghel
Director
Raphael Hofstein
Director
Sandra Panem
Director

Shareholders

Name
Position
Philip Serlin
Chief Executive Officer
Mali Zeevi
Chief Financial Officer
Abi Vainstein Haras
Vice President Clinical Development
Ella Sorani
Vice President Research and Development